NCT00866554 - Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2019

Study Completion Date

December 31, 2019

Conditions

Prostate CancerErectile DysfunctionLower Urinary Tract Symptoms

Interventions

DRUG

administration of a LHRH agonist and Bicalutamide

3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.

DRUG

administration of Bicalutamide, Dutasteride and Tamoxifen

"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."

Trial Locations (1)

G1R 2J6

CHUQ- Hotel-Dieu de Quebec, Québec